InterMune, Inc.
News and overview for InterMune, Inc.
Alkermes gains; Cerus, InterMune tumble - MarketWatch
MarketWatch | 6 days 5 hours 13 minutes ago
Shares of Alkermes /quotes/comstock/15*!alks/quotes/nls/alks (ALKS 8.91, +0.73, +8.92%) were up 10% at $9.02.
InterMune Announces Modification to On-Going Phase 2b Study of ITMN-191 in Patients with Chronic HCV Infection [Press Release]
PRNewswire | 6 days 2 hours 8 minutes ago
InterMune Announces Modification to On-Going...Nov. 17 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced that the on-going...well-tolerated in these studies. InterMune is a biotechnology company focused on...
InterMune Reports Third Quarter 2009 Financial Results and Business Highlights [Press Release]
PRNewswire | 17 days 18 hours 38 minutes ago
BRISBANE, Calif., Nov. 5 /PRNewswire-FirstCall/ -- InterMune, Inc.
InterMune Announces Appointments of Senior Leadership to Prepare for Potential Launch of Pirfenidone [Press Release]
PRNewswire | 18 days 2 hours 38 minutes ago
BRISBANE, Calif., Nov. 5 /PRNewswire-FirstCall/ -- InterMune, Inc.
InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF [Press Release]
PRNewswire | 19 days 1 hour 47 minutes ago
...PRNewswire-FirstCall/ -- InterMune, Inc. today announced that it...gastrointestinal symptoms. InterMune licensed pirfenidone from Marnac, Inc. and its co-licensor... CONTACT: Jim Goff of InterMune, Inc., +1-415-466-2228...
InterMune seeks FDA marketing approval for pirfenidone
News-Medical.Net | 18 days 14 hours 18 minutes ago
InterMune, Inc. (Nasdaq: ITMN) today announced that it has submitted an electronic New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF). Pirfenidone has been granted Orphan Drug and Fast Track designation by the FDA, and also has been granted Orphan Drug status in Europe.
InterMune Announces Initiation of Ritonavir-Boosted ITMN-191/RG7227 Study in HCV Patients [Press Release]
PRNewswire | 55 days 10 hours 35 minutes ago
...Sept. 29 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced that its partner Roche...intermune.com. CONTACT: Jim Goff of InterMune, Inc., +1-415-466-2228, jgoff@intermune.com
InterMune to Release Third Quarter Financial Results on November 5 [Press Release]
PRNewswire | 25 days 5 hours 38 minutes ago
...Calif., Oct. 29 /PRNewswire-FirstCall/ -- InterMune, Inc. announced today that it will release third...intermune.com. CONTACT: Jim Goff of InterMune, Inc., +1-415-466-2228, jgoff@intermune.com
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights [Press Release]
PRNewswire | 109 days 1 hour 36 minutes ago
BRISBANE, Calif., Aug. 6 /PRNewswire-FirstCall/ -- InterMune, Inc.
InterMune to Present at Oppenheimer Conference [Press Release]
PRNewswire | 24 days 20 hours 37 minutes ago
...Calif., Oct. 29 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced that Dan Welch, Chairman...www.intermune.com. CONTACT: Jim Goff of InterMune, Inc., +1-415-466-2228, jgoff@intermune.com
InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis [Press Release]
PRNewswire | 67 days 10 hours 36 minutes ago
...Sept. 17 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced that it will be collaborating...nationaljewish.org. CONTACT: Jim Goff of InterMune, Inc., +1-415-466-2228, jgoff@intermune.com
INFORM-1 Results: Robust Antiviral Suppression Achieved with Combination of Nucleoside Analog Polymerase Inhibitor RG7128 and Protease Inhibitor RG7227 [Press Release]
PRNewswire | 20 days 2 hours 22 minutes ago
...Nov. 3 /PRNewswire-FirstCall/ -- InterMune, Inc. and Pharmasset, Inc. today announced...Sr. Director, Corp. Comm. & IR of InterMune, Inc.,+1-415-466-2228, jgoff@intermune.com; or Richard E. T. Smith, Ph...
Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting [Press Release]
PRNewswire | 70 days 7 hours 36 minutes ago
VIENNA, Sept. 14 /PRNewswire-FirstCall/ -- InterMune, Inc.
Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C [Press Release]
PRNewswire | 96 days 1 hour 7 minutes ago
Roche and InterMune Initiate Phase 2b Clinical Trial of...VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. today announced that the first patient...developed in partnership by Roche and InterMune. Initiation of the Phase 2b trial...
InterMune to Present at JMP Securities Conference [Press Release]
PRNewswire | 53 days 10 hours 35 minutes ago
...Calif., Oct. 1 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced that Dan Welch, Chairman...www.intermune.com. CONTACT: Jim Goff of InterMune, Inc., +1-415-466-2228, jgoff@intermune.com
Sign up for FDLI SmartBrief
Company Overview
| Company: | InterMune, Inc. |
|---|---|
| Industry: | Biopharmaceuticals & Biotherapeutics |
| Website: | http://www.intermune.com |
InterMune has found a good thing in interferon gamma. The company's sole marketed product is Actimmune (interferon gamma-1b), an FDA-approved treatment for two rare congenital disorders: chronic granulomatous disease, an immune condition; and osteopetrosis, a disease causing abnormal bone growth. Most of Actimmune's sales, however, are for off-label use of the drug to treat the deterioration of lung function from scarring caused by idiopathic pulmonary fibrosis (IPF). InterMune is developing another potential IPF treatment called pirfenidone, and it is also researching hepatitis C therapies with Roche.
Key Numbers
| Sales in U.S. Dollars (mil.) | 48.2 (2008) |
|---|---|
| One-year % Growth in Sales | -27.8 (2008) |
| Net Income in U.S. Dollars (mil.) | -97.7 (2008) |
| One-year % Growth in Net Income | 0.0 (2008) |
| Number of Employees | 130 (2008) |
| One-year % Growth in Number of Employees | -1.5 (2008) |
| Fiscal Year-End | December |